Home › Funds › Eversept Partners, LP › PCVX

Eversept Partners, LP position in PCVX

VAXCYTE INC · Health Care

Eversept Partners, LP reported holding 629,952 shares of PCVX (VAXCYTE INC) in its Q2 2026 13F filing — a position valued at US$36.6M, representing 1.92% of its reported portfolio and ranking #15 among its reported holdings. Eversept Partners, LP has disclosed PCVX holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)629.95K sh
Reported value held$36.62M
Portfolio Weight1.92%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Eversept Partners, LP's PCVX position evolved

Eversept Partners, LP first disclosed a stake in PCVX in Q3 2023 at 190,430 shares (US$9.7M). The position peaked in Q4 2025 at 1,197,722 shares, worth US$55.3M. Across 11 filings, Eversept Partners, LP increased the stake 4 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 629,952 shares valued at US$36.6M — a reduction of -294,241 shares quarter over quarter.. Notable position changes include a 51% trim in Q2 2024 (shares rose 51% over the following quarter), a 337% increase in Q1 2025 (shares fell 14% over the following quarter), a 133% increase in Q2 2025 (shares rose 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 190.43K $9.71M New
Q4 2023 233.84K $14.69M Add
Q1 2024 197.33K $13.48M Reduce
Q2 2024 96.09K $7.26M Reduce
Q4 2024 127.59K $10.44M New
Q1 2025 557.07K $21.03M Add
Q2 2025 1.30M $42.21M Add
Q3 2025 1.42M $51.22M Add
Q4 2025 1.20M $55.26M Reduce
Q1 2026 924.19K $53.70M Reduce
Q2 2026 629.95K $36.62M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PCVX and 13F data

PCVX (VAXCYTE INC) is a Health Care company. 36 other funds we track also report a position in PCVX — the largest reported positions include Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PCVX

All PCVX fund holders →

FAQ

How long has Eversept Partners, LP held PCVX?

Eversept Partners, LP has disclosed PCVX holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

What is Eversept Partners, LP's current position in PCVX?

As of Q2 2026, Eversept Partners, LP holds 629.95K shares of PCVX (VAXCYTE INC), valued at $36.62M, representing 1.92% of its reported portfolio and ranking #15.

Has Eversept Partners, LP been buying or selling PCVX?

In the latest 13F filing (Q2 2026), Eversept Partners, LP reduced its position in PCVX. The position peaked in Q4 2025 at 1.20M shares.

Which other funds hold PCVX?

Other major institutional holders of PCVX include Jupiter Topco LLC, Janus Henderson Group, T. Rowe Price Investment Management, Inc., among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.